Obrador E, Moreno-Murciano P, Oriol-Caballo M, Lopez-Blanch R, Pineda B, Gutierrez-Arroyo J
Int J Mol Sci. 2024; 25(5).
PMID: 38473776
PMC: 10931797.
DOI: 10.3390/ijms25052529.
Roncevic A, Koruga N, Soldo Koruga A, Roncevic R, Rotim T, Simundic T
Biomedicines. 2023; 11(6).
PMID: 37371674
PMC: 10296009.
DOI: 10.3390/biomedicines11061579.
Mantica M, Drappatz J
Front Oncol. 2023; 13:1124198.
PMID: 36874119
PMC: 9981156.
DOI: 10.3389/fonc.2023.1124198.
Zhao T, Li C, Ge H, Lin Y, Kang D
Chin Neurosurg J. 2022; 8(1):2.
PMID: 35045874
PMC: 8766628.
DOI: 10.1186/s41016-021-00269-7.
Wu W, Klockow J, Zhang M, Lafortune F, Chang E, Jin L
Pharmacol Res. 2021; 171:105780.
PMID: 34302977
PMC: 8384724.
DOI: 10.1016/j.phrs.2021.105780.
Current State of Immunotherapy for Treatment of Glioblastoma.
McGranahan T, Therkelsen K, Ahmad S, Nagpal S
Curr Treat Options Oncol. 2019; 20(3):24.
PMID: 30790064
PMC: 6394457.
DOI: 10.1007/s11864-019-0619-4.
The development of dendritic cell vaccine-based immunotherapies for glioblastoma.
Reardon D, Mitchell D
Semin Immunopathol. 2017; 39(2):225-239.
PMID: 28138787
DOI: 10.1007/s00281-016-0616-7.
Acute hemorrhagic leukoencephalomyelitis in a man with viral myocarditis.
Kitulwatte I, Kim P, Pollanen M
Forensic Sci Med Pathol. 2015; 11(3):416-20.
PMID: 26148811
DOI: 10.1007/s12024-015-9692-6.
Dendritic cell immunotherapy for solid tumors: evaluation of the DCVax® platform in the treatment of glioblastoma multiforme.
Hdeib A, Sloan A
CNS Oncol. 2015; 4(2):63-9.
PMID: 25768330
PMC: 6093019.
DOI: 10.2217/cns.14.54.
DCVax®-L--developed by Northwest Biotherapeutics.
Polyzoidis S, Ashkan K
Hum Vaccin Immunother. 2014; 10(11):3139-45.
PMID: 25483653
PMC: 4514134.
DOI: 10.4161/hv.29276.
Rindopepimut: a promising immunotherapeutic for the treatment of glioblastoma multiforme.
Swartz A, Li Q, Sampson J
Immunotherapy. 2014; 6(6):679-90.
PMID: 25186601
PMC: 4524671.
DOI: 10.2217/imt.14.21.
Antibody, T-cell and dendritic cell immunotherapy for malignant brain tumors.
Chandramohan V, Mitchell D, Johnson L, Sampson J, Bigner D
Future Oncol. 2013; 9(7):977-90.
PMID: 23837761
PMC: 3904373.
DOI: 10.2217/fon.13.47.
Immunotherapy of brain cancers: the past, the present, and future directions.
Ge L, Hoa N, Bota D, Natividad J, Howat A, Jadus M
Clin Dev Immunol. 2011; 2010:296453.
PMID: 21437175
PMC: 3061456.
DOI: 10.1155/2010/296453.
Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy.
Prins R, Soto H, Konkankit V, Odesa S, Eskin A, Yong W
Clin Cancer Res. 2010; 17(6):1603-15.
PMID: 21135147
PMC: 3071163.
DOI: 10.1158/1078-0432.CCR-10-2563.
Dendritic cell vaccines for brain tumors.
Kim W, Liau L
Neurosurg Clin N Am. 2009; 21(1):139-57.
PMID: 19944973
PMC: 2810429.
DOI: 10.1016/j.nec.2009.09.005.
An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme.
Sampson J, Archer G, Mitchell D, Heimberger A, Herndon 2nd J, Lally-Goss D
Mol Cancer Ther. 2009; 8(10):2773-9.
PMID: 19825799
PMC: 2991139.
DOI: 10.1158/1535-7163.MCT-09-0124.
The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients.
Heimberger A, Sampson J
Expert Opin Biol Ther. 2009; 9(8):1087-98.
PMID: 19591631
PMC: 2793529.
DOI: 10.1517/14712590903124346.
Human glioma cell culture: two FCS-free media could be recommended for clinical use in immunotherapy.
Clavreul A, Jean I, Preisser L, Chassevent A, Sapin A, Michalak S
In Vitro Cell Dev Biol Anim. 2009; 45(9):500-11.
PMID: 19533255
DOI: 10.1007/s11626-009-9215-4.
Immunotherapeutic approaches for glioma.
Okada H, Kohanbash G, Zhu X, Kastenhuber E, Hoji A, Ueda R
Crit Rev Immunol. 2009; 29(1):1-42.
PMID: 19348609
PMC: 2713019.
DOI: 10.1615/critrevimmunol.v29.i1.10.
Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma.
Sampson J, Archer G, Mitchell D, Heimberger A, Bigner D
Semin Immunol. 2008; 20(5):267-75.
PMID: 18539480
PMC: 2633865.
DOI: 10.1016/j.smim.2008.04.001.
